Cardiff Oncology to Present at Three Investor Conferences in September 2025

Cardiff Oncology to participate in three investor conferences in September 2025. CEO Mark Erlander will present at the H.C. Wainwright conference on September 9. Investors can access a live webcast of the presentation on the Cardiff Oncology website. The company is advancing its lead asset, onvansertib, in clinical trials targeting various cancers.

Title: Cardiff Oncology to Participate in Three Major Investor Conferences in September 2025

Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotech company focused on PLK1 inhibition for cancer therapies, has announced its participation in three major investor conferences in September 2025. The company will attend the Wells Fargo Healthcare Conference (09/05), the Morgan Stanley Global Healthcare Conference (09/08), and the H.C. Wainwright Global Investment Conference (09/09). CEO Mark Erlander will present a fireside chat at the H.C. Wainwright conference at 10:30 AM ET, which will be available via webcast on the company's website.

Details of the Events

- Wells Fargo 20th Annual Healthcare Conference
- Format: 1x1 Meetings
- Date: 09/05/2025
- Location: Encore Boston Harbor, Everett, MA

- Morgan Stanley 23rd Annual Global Healthcare Conference
- Format: 1x1 Meetings
- Date: 09/08/2025
- Location: Sheraton New York Times Square, New York, NY

- H.C. Wainwright 27th Annual Global Investment Conference
- Format: Fireside Chat and 1x1 Meetings
- Presenter: Mark Erlander, CEO
- Date: 09/09/2025
- Time: 10:30 AM ET
- Location: Lotte New York Palace Hotel, New York, NY

Interested parties can register for and access the live webcast for the H.C. Wainwright conference by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.

About Cardiff Oncology

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing and planned investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). These programs and the company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone.

Contact Information

For more information, please visit [Cardiff Oncology's website](https://www.cardiffoncology.com).

- James Levine
- Chief Financial Officer
- 858-952-7670
- jlevine@cardiffoncology.com

- Kiki Patel, PharmD
- Gilmartin Group
- 332-895-3225
- Kiki@gilmartinir.com

- Meghan Bianco
- Taft Communications, a division of RF|Binder
- 609-544-5446

References

[1] https://www.stocktitan.net/news/CRDF/cardiff-oncology-to-participate-in-three-upcoming-investor-gsbi69m43aub.html
[2] https://www.businesswire.com/news/home/20250611108031/en/U.S.-Food-and-Drug-Administration-Approves-Nuvation-Bios-IBTROZIeltasrectinib-a-Next-Generation-Oral-Treatment-for-Advanced-ROS1-Positive-Non-Small-Cell-Lung-Cancer